This 2023 randomized, double-blind, placebo-controlled trial by Grilo et al. assessed the efficacy of naltrexone/bupropion (NB) as a maintenance treatment for adults with binge-eating disorder (BED) and comorbid obesity who had responded to acute treatment. Sixty-six participants (84.8% women; mean age 46.9; mean BMI 34.9 kg/m²) who achieved remission following
